Info

🌱來自: ovarian cancer

Treatment of ovarian cancer

• Cytoreductive surgery: survival benefit even for stage IV and relapsed disease (Gynecol Oncol 2013;130:493; NEJM 2021;385:2123). Consider neoadj. chemo to ↑ likelihood of maximal cytoreduction at surgery and reduce surgical morbidity. • Chemo: 1st line (neoadj., adj., adv.): carboplatin+paclitaxel (CP). PARPi maintenance (olaparib, niraparib, rucaparib; esp if homologous recombination deficient [eg, BRCA1/2]) or bevacizumab maintenance if homologous recombination proficient. • Recurrence at >6 mos = platinum sensitive → Rx w/ platinum doublet. If <6 mos = platinum resistant → single agent chemo (eg, liposomal doxorubicin, gemcitabine) ± bevacizumab.